Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.26 EUR | +3.67% | +7.11% | -13.74% |
Apr. 15 | Sanofi: progress in hematology trial | CF |
Apr. 15 | Innate Pharma: progress in hematology trial | CF |
Sales 2024 * | 46.78M 50.18M | Sales 2025 * | 74.41M 79.82M | Capitalization | 176M 189M |
---|---|---|---|---|---|
Net income 2024 * | -25M -26.82M | Net income 2025 * | -21M -22.52M | EV / Sales 2024 * | 2.36 x |
Net cash position 2024 * | 65.68M 70.45M | Net cash position 2025 * | 122M 130M | EV / Sales 2025 * | 0.73 x |
P/E ratio 2024 * |
-15
x | P/E ratio 2025 * |
3.6
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.91% |
Latest transcript on Innate Pharma
1 day | -2.46% | ||
1 week | +1.40% | ||
Current month | -0.23% | ||
3 months | -14.84% | ||
6 months | -7.23% | ||
Current year | -16.79% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 60 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.26 | +3.67% | 26 983 |
24-04-25 | 2.18 | -2.46% | 19,133 |
24-04-24 | 2.235 | -1.11% | 60,896 |
24-04-23 | 2.26 | +4.39% | 79,753 |
24-04-22 | 2.165 | +2.61% | 34,564 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.79% | 189M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- IPH Stock